On June 8, 2020, Rigenerand SRL (https://rigenerand-biotech.com/), a biotech company in Italy that both develops and manufactures medicinal products for cell therapy applications, primarily for regenerative medicine and oncology, announced it has commenced development of a novel 3D bioreactor and pipeline, specifically designed for the incremental production of extracellular vesicles including exosomes (collectively termed EVs) in a cGMP (current Good Manufacturing Practice) environment. Rigenerand’s project development will be supported with part of a grant of EUR 4.4 million (almost $5 million) from Horizon 2020 for the H2020-EU.1.2.2.-FET Proactive program, awarded to the Biogenic Organotropic Wetsuits project (https://cordis.europa.eu/project/id/952183). This project comprises a consortium of companies involving Rigenerand. The Biogenic Organotropic Wetsuits (Grant Agreement ID: 952183) project involves eleven organizations across seven countries in Europe. Rigenerand will contribute to the consortium its combination of expertise, technology, and innovation focused on biomaterials, prototypes production, and industrialization of cell culture devices and 3D cell cultures. Rigenerand will start developing novel ways of improving current EV cGMP production technologies. These technologies ultimately aim to produce EV clinical batches to be used as drug substances for cell-free therapy medicinal products.
Login Or Register To Read Full Story